Last reviewed · How we verify
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of JNJ-64232025 following single ascending intravenous (IV) study intervention administrations and a single subcutaneous (SC) intervention administration in healthy participants.
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | Fri Jun 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- JNJ-64232025 IV
- JNJ-64232025 SC
- Placebo
Countries
Belgium